Crescent Biopharma (CBIO) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T14:16:05.023Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:16:05.023Z.

Quote observation: 2026-10-06T14:15:17.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -168,258,000
Quote market capitalization: 530,415,463
Total debt · period ending 2026-06-30: 1,437,000
Cash · period ending 2026-06-30: 171,593,000

FMP input reference: efaaa36d31f915a5dffaa91b800fc30e2d7f64892a7236e7a1e7b68ff3f7d584

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

CBIO EBITDA Yield Metrics

EBITDA YIELD

N/A

CBIO Competitors' EBITDA Yield

CBIO

Crescent Biopharma, Inc.

Current

Market Cap

$530.42M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMMX

Immix Biopharma, Inc.

vs CBIO

Market Cap

$526.07M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MASS

908 Devices Inc.

vs CBIO

Market Cap

$525.15M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DCTH

Delcath Systems, Inc.

vs CBIO

Market Cap

$536.12M

EBITDA Yield

N/A

TTM Avg

1.23%

3Y Avg

1.23%

5Y Avg

1.23%

ALT

Altimmune, Inc.

vs CBIO

Market Cap

$515.36M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MNPR

Monopar Therapeutics Inc.

vs CBIO

Market Cap

$510.90M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALLO

Allogene Therapeutics, Inc.

vs CBIO

Market Cap

$503.41M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTMX

CytomX Therapeutics, Inc.

vs CBIO

Market Cap

$549.35M

EBITDA Yield

N/A

TTM Avg

31.68%

3Y Avg

26.65%

5Y Avg

26.65%

MMEDV

MiniMed Group, Inc.

vs CBIO

Market Cap

$560.00M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AQST

Aquestive Therapeutics, Inc.

vs CBIO

Market Cap

$562.72M

EBITDA Yield

N/A

TTM Avg

2.38%

3Y Avg

2.38%

5Y Avg

2.38%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Crescent Biopharma, Inc. (CBIO)	$530.42M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$526.07M	N/A	N/A	N/A	N/A
908 Devices Inc. (MASS)vs ›	$525.15M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$536.12M	N/A	1.23%	1.23%	1.23%
Altimmune, Inc. (ALT)vs ›	$515.36M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$510.90M	N/A	N/A	N/A	N/A
Allogene Therapeutics, Inc. (ALLO)vs ›	$503.41M	N/A	N/A	N/A	N/A
CytomX Therapeutics, Inc. (CTMX)vs ›	$549.35M	N/A	31.68%	26.65%	26.65%
MiniMed Group, Inc. (MMEDV)vs ›	$560.00M	N/A	N/A	N/A	N/A
Aquestive Therapeutics, Inc. (AQST)vs ›	$562.72M	N/A	2.38%	2.38%	2.38%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

CBIO EBITDA Yield Metrics

CBIO Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics